Severity of Disease and Clinical Outcomes in Patients With Hospital-Acquired Pneumonia Due to Methicillin-Resistant Staphylococcus aureus Strains Not Influenced by the Presence of the Panton-Valentine Leukocidin Gene
Authors:
- Julio A. RamirezJRJulio A. Ramirez
- the IMPACT-HAP Study GroupTGthe IMPACT-HAP Study Group
Open Access
- 31 August 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 53 (8) , 766-771
Abstract
(See the article by Hota et al, on pages 757–65 .) Background. Patients with community-acquired pneumonia (CAP) infected with methicillin-resistant Staphylococcus aureus (MRSA) strains carrying the Panton-Valentine leukocidin (PVL) gene have severe clinical presentation and poor clinical outcomes. Antibiotics that suppress toxin production have been suggested for the management of these patients. The objective of this study was to compare the severity of disease and clinical outcomes of patients with hospital-acquired pneumonia/ventilator-associated pneumonia (HAP/VAP) infected with MRSA carrying the PVL gene with those patients infected with MRSA strains that do not carry the PVL gene. Methods. This was a multicenter observational study of patients with HAP and VAP. MRSA isolates were subjected to genetic analysis to define the presence of the PVL gene, the USA type and the staphylococcal cassette chromosome mec type. Severity of disease was evaluated with the Acute Physiology and Chronic Health Evaluation II (APACHE II) score. The primary clinical outcome was mortality at hospital discharge. Results. A total of 109 cases of MRSA HAP/VAP were evaluated. The incidence of PVL+ MRSA was 27%. APACHE II score at diagnosis of HAP/VAP was 21 ± 8 for PVL+ MRSA and 20 ± 6 for PVL− MRSA (P = .67). Mortality was 10% (3/29) for patients with PVL+ MRSA versus 10% (8/80) for patients with PVL− MRSA (P > .99). Conclusions. In patients with HAP or VAP due to MRSA, severity of disease and clinical outcomes are not influenced by the presence of the PVL gene. Therapeutic strategies directed to block PVL exotoxin may not impact outcomes in these patients.Keywords
This publication has 15 references indexed in Scilit:
- Panton‐Valentine Leukocidin Is Not a Virulence Determinant in Murine Models of Community‐Associated Methicillin‐ResistantStaphylococcus aureusDiseaseThe Journal of Infectious Diseases, 2008
- Molecular Epidemiology of Methicillin-Resistant Staphylococcus aureus Bloodstream Isolates in Urban DetroitJournal of Clinical Microbiology, 2008
- Pneumonia Caused by Methicillin‐ResistantStaphylococcus aureusClinical Infectious Diseases, 2008
- Are Community-Associated Methicillin-Resistant Staphylococcus aureus (MRSA) Strains Replacing Traditional Nosocomial MRSA Strains?Clinical Infectious Diseases, 2008
- Effect of Antibiotics on Staphylococcus aureus Producing Panton-Valentine LeukocidinAntimicrobial Agents and Chemotherapy, 2007
- Staphylococcus aureus Panton-Valentine Leukocidin Causes Necrotizing PneumoniaScience, 2007
- Community-associated Methicillin-resistantStaphylococcus aureusIsolates and Healthcare-Associated Infections1Emerging Infectious Diseases, 2007
- Methicillin-ResistantS. aureusInfections among Patients in the Emergency DepartmentNew England Journal of Medicine, 2006
- Severe Community-Onset Pneumonia in Healthy Adults Caused by Methicillin-Resistant Staphylococcus aureus Carrying the Panton-Valentine Leukocidin GenesClinical Infectious Diseases, 2005
- APACHE IICritical Care Medicine, 1985